Clinical

Latest News


Latest Videos


CME Content


More News

Video 12 - "The Future of Ph+ ALL Treatments"

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

FDA approval indication | Image Credit: Dzmitry - stock.adobe.com

Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo